Using the WGS data, we assessed the presence of variants and/or mutations in several genes that are known to be frequently mutated in prostate cancer (BRCA1, BRCA2, RB, PTEN, CDK12, PI3K, ADP-ribose, PIK3GA, PIK3CB and PIK3R1, AKT, CYP17, IGF 1, EGF, and BCL2; Supplementary Table S3). This evidence concerns the gene BRCA2 and prostate cancer.